News | May 07, 2021
Lonza announces expansion plans for mammalian manufacturing facilities
The facility is expected to be completed in 2024
The facility is expected to be completed in 2024
Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution USP, 2% and 0.5% has an estimated market size of US $80 million for twelve months ending December 2020 according to IQVIA
Seven manufacturers of Remdesivir have increased production capacity to 1.03 crore vials per month up from 38 lakh vials per month a month ago
R&D Centre will be housed in Baddi and will cater to all business divisions in addition to expansion plans for all its verticals including APls, Formulations and Medical Devices
First company in the world to launch Ryaltris-AZ, as a novel fixed dose combination of Mometasone furoate 50 mcg + Azelastine 140 mcg
The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.
The Government of India has started importing the vital drug Remdesivir from other countries to ease out the shortage of Remdesivir in the country
Dr. Reddy’s Albendazole Tablets, USP are available in 200 mg tablets in bottle count sizes of two
New agreement for three further production lines at Lonza’s site in Visp, Switzerland
Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong
Subscribe To Our Newsletter & Stay Updated
